{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:24:16Z","timestamp":1768454656889,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1245\/s10434-021-10048-4","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T22:22:38Z","timestamp":1620080558000},"page":"7109-7117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cytoreductive Surgery Plus HIPEC With and Without NIPEC for Malignant Peritoneal Mesothelioma: A Propensity-Matched Analysis"],"prefix":"10.1245","volume":"28","author":[{"given":"Paul H.","family":"Sugarbaker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"issue":"6","key":"10048_CR1","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s10552-009-9328-9","volume":"20","author":"SH Moolgavkar","year":"2009","unstructured":"Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973\u20132005. Cancer Causes Control. 2009;20(6):935\u201344.","journal-title":"Cancer Causes Control"},{"issue":"10","key":"10048_CR2","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1177\/000313480106701019","volume":"67","author":"BW Loggie","year":"2001","unstructured":"Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg. 2001;67(10):999\u20131003.","journal-title":"Am Surg"},{"issue":"3","key":"10048_CR3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S1055-3207(03)00045-0","volume":"12","author":"PH Sugarbaker","year":"2003","unstructured":"Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003;12(3):605\u201321.","journal-title":"Surg Oncol Clin N Am"},{"issue":"24","key":"10048_CR4","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1200\/JCO.2003.04.150","volume":"21","author":"AL Feldman","year":"2003","unstructured":"Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21(24):4560\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"10048_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1245\/ASO.2006.03.045","volume":"13","author":"M Deraco","year":"2006","unstructured":"Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13(2):229\u201337.","journal-title":"Ann Surg Oncol"},{"key":"10048_CR6","doi-asserted-by":"publisher","first-page":"664s","DOI":"10.1200\/jco.2005.23.16_suppl.7175","volume":"23","author":"RN Taub","year":"2005","unstructured":"Taub RN, Hesdorffer ME, Keohan ML. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma (MPM). J Clin Oncol. 2005;23:664s.","journal-title":"J Clin Oncol"},{"issue":"3","key":"10048_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1245\/ASO.2006.05.041","volume":"13","author":"C Brigand","year":"2006","unstructured":"Brigand C, Monneuse O, Mohamed F, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006;13(3):405\u201312.","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10048_CR8","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/S0399-8320(07)73964-7","volume":"31","author":"D Elias","year":"2007","unstructured":"Elias D, Bedard V, Bouzid T, et al. Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol. 2007;31(10):784\u20138.","journal-title":"Gastroenterol Clin Biol"},{"issue":"9","key":"10048_CR9","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.ejso.2008.09.010","volume":"35","author":"H Yano","year":"2009","unstructured":"Yano H, Moran BJ, Cecil TD, Murphy EM. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma. Eur J Surg Oncol. 2009;35(9):980\u20135.","journal-title":"Eur J Surg Oncol"},{"issue":"10","key":"10048_CR10","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1245\/s10434-010-1080-6","volume":"17","author":"AU Blackham","year":"2010","unstructured":"Blackham AU, Shen P, Stewart JH, Russell GB, Levine EA. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol. 2010;17(10):2720\u20137.","journal-title":"Ann Surg Oncol"},{"key":"10048_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/jso.21177","volume":"99","author":"TC Chua","year":"2009","unstructured":"Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: The Australian Experience. J Surg Oncol. 2009;99:109\u201313.","journal-title":"J Surg Oncol"},{"key":"10048_CR12","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2010","unstructured":"Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2010;27:6237\u201342.","journal-title":"J Clin Oncol"},{"key":"10048_CR13","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","volume":"22","author":"JH Helm","year":"2015","unstructured":"Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: A systematic review and meta-analysis. Ann Surg Oncol. 2015;22:1686\u201393.","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10048_CR14","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1200\/JOP.2016.011908","volume":"12","author":"PH Sugarbaker","year":"2016","unstructured":"Sugarbaker PH, Turaga KK, Alexander HR Jr, Deraco M, Hesdorffer M. Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy. J Oncol Pract. 2016;12(10):928\u201335.","journal-title":"J Oncol Pract"},{"key":"10048_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/jso.21388","volume":"100","author":"M Deraco","year":"2009","unstructured":"Deraco M, Baratti D, Kusamura S, Laterza B, Balestra MR. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol. 2009;100:321\u20138.","journal-title":"J Surg Oncol"},{"issue":"5","key":"10048_CR16","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1245\/s10434-012-2237-2","volume":"19","author":"D Baratti","year":"2012","unstructured":"Baratti D, Kusamura S, Cabras AD, Deraco M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol. 2012;19(5):1416\u201324.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10048_CR17","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.ejso.2017.01.009","volume":"43","author":"PH Sugarbaker","year":"2017","unstructured":"Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol. 2017;43(7):1228\u201335.","journal-title":"Eur J Surg Oncol"},{"key":"10048_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34\u201343.","journal-title":"N Engl J Med"},{"issue":"1","key":"10048_CR19","first-page":"49","volume":"15","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15(1):49\u201358.","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"10048_CR20","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.ejso.2006.05.009","volume":"32","author":"TD Yan","year":"2006","unstructured":"Yan TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32(9):948\u201353.","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"10048_CR21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1245\/ASO.2006.03.079","volume":"13","author":"PH Sugarbaker","year":"2006","unstructured":"Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol. 2006;13(5):635\u201344.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10048_CR22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1245\/s10434-006-9187-5","volume":"14","author":"TD Yan","year":"2007","unstructured":"Yan TD, Edwards G, Alderman R, et al. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma\u2014a prospective study of 70 consecutive cases. Ann Surg Oncol. 2007;14(2):515\u201325.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10048_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","volume":"100","author":"JL Walker","year":"2006","unstructured":"Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006;100(1):27\u201332.","journal-title":"Gynecol Oncol"},{"key":"10048_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","volume":"221","author":"PH Sugarbaker","year":"1995","unstructured":"Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29\u201342.","journal-title":"Ann Surg"},{"key":"10048_CR25","unstructured":"Sugarbaker PH, van der Speeten K. An overview of peritonectomy, visceral resection, and therapeutic laparoscopy for peritoneal surface malignancy. In: Sugarbaker PH (ed). Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. Textbook and Video Atlas. 2nd Edition. Woodbury, CT: Cine-Med Publishing; 2017. pp. 17\u201346."},{"key":"10048_CR26","unstructured":"Van der Speeten K, Stuart OA, Sugarbaker PH. Cancer chemotherapy for peritoneal metastases: Pharmacology and treatment. In: Sugarbaker PH (ed). Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. Textbook and Video Atlas. 2nd Edition. Woodbury, CT: Cine-Med Publishing; 2017. pp. 47\u201382."},{"key":"10048_CR27","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/185092","author":"K Van der Speeten","year":"2011","unstructured":"Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. Pharmacokinetic study of perioperative intravenous ifosfamide. Int J Surg Oncol. 2011. https:\/\/doi.org\/10.1155\/2011\/185092.","journal-title":"Int J Surg Oncol."},{"issue":"5","key":"10048_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00280-003-0680-2","volume":"52","author":"F Mohamed","year":"2003","unstructured":"Mohamed F, Marchettini P, Stuart OA, Sugarbaker PH. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemother Pharmacol. 2003;52(5):405\u201310.","journal-title":"Cancer Chemother Pharmacol"},{"key":"10048_CR29","first-page":"752643","volume":"2012","author":"PH Sugarbaker","year":"2012","unstructured":"Sugarbaker PH, Bijelic L. Adjuvant bidirectional chemotherapy using an intraperitoneal port. Gastroenterol Res Pract. 2012;2012:752643.","journal-title":"Gastroenterol Res Pract."},{"key":"10048_CR30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.suronc.2020.01.009","volume":"33","author":"PH Sugarbaker","year":"2020","unstructured":"Sugarbaker PH, Stuart OA. Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with intraperitoneal paclitaxel. Surg Oncol. 2020;33:96\u20139.","journal-title":"Surg Oncol"},{"key":"10048_CR31","unstructured":"Gant T, Crowland K. A practical guide to getting started with propensity scores. Paper 689-2017. Available at: https:\/\/support.sas.com\/resources\/papers\/proceedings17\/0689-2017.pdf."},{"issue":"1","key":"10048_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1245\/s10434-006-9169-7","volume":"14","author":"TD Yan","year":"2007","unstructured":"Yan TD, Brun EA, Cerruto CA, Haveric N, Chang D, Sugarbaker PH. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2007;14(1):41\u20139.","journal-title":"Ann Surg Oncol"},{"key":"10048_CR33","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/cncr.20836","volume":"15","author":"TD Yan","year":"2005","unstructured":"Yan TD, Haveric N, Carmignani P, Chang D, Sugarbaker PH. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer. 2005;15:839\u201349.","journal-title":"Cancer"},{"key":"10048_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2016.06.002","volume":"65","author":"V Kepenekian","year":"2016","unstructured":"Kepenekian V, Elias D, Passot G, et al. Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: multi-Institutional Retrospective Study. Eur J Cancer. 2016;65:69\u201379.","journal-title":"Eur J Cancer"},{"issue":"6","key":"10048_CR35","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/01243894-200607000-00002","volume":"1","author":"PA J\u00e4nne","year":"2006","unstructured":"J\u00e4nne PA, Wozniak AJ, Belani CP, et al. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol. 2006;1(6):506\u201312.","journal-title":"J Thorac Oncol"},{"key":"10048_CR36","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-2020-3","author":"PH Sugarbaker","year":"2020","unstructured":"Sugarbaker PH. Intraperitoneal paclitaxel: pharmacology, clinical results and future prospects focused issue: intraperitoneal chemotherapy for peritoneal metastases: HIPEC, EPIC, NIPEC, PIPAC and more. J Gastrointestinal Oncol. 2020. https:\/\/doi.org\/10.21037\/jgo-2020-3. (in press).","journal-title":"J Gastrointestinal Oncol."},{"key":"10048_CR37","first-page":"871","volume":"290","author":"HJ Kuh","year":"1999","unstructured":"Kuh HJ, Jang SH, Wientjes MG, et al. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther. 1999;290:871\u201380.","journal-title":"J Pharmacol Exp Ther"},{"key":"10048_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2021.04.012","author":"PH Sugarbaker","year":"2021","unstructured":"Sugarbaker PH, Chang D, Jelinek JS. Concerning CT features predict outcome of treatment in patients with malignant peritoneal mesothelioma. Eur J Surg Oncol. 2021. https:\/\/doi.org\/10.1016\/j.ejso.2021.04.012. (in press).","journal-title":"Eur J Surg Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10048-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-10048-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10048-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T07:58:19Z","timestamp":1672041499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-10048-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10048"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-10048-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,3]]},"assertion":[{"value":"4 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Paul H. Sugarbaker and David Chang have no disclosures to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Diclosures"}}]}}